
Reset all filters
01 3Dysval
02 5Ingrezza
Main Therapeutic Indication : Neurology
Currency : USD
2020 Revenue in Millions : 993
2019 Revenue in Millions : 753
Growth (%) : 32
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 1,082
2020 Revenue in Millions : 993
Growth (%) : 9
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 1,428
2021 Revenue in Millions : 1,082
Growth (%) : 32
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 24
2021 Revenue in Millions : 0
Growth (%) : New Launch in 2022
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 1,836
2022 Revenue in Millions : 1,428
Growth (%) : 29
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 28
2022 Revenue in Millions : 24
Growth (%) : 31
Main Therapeutic Indication : Neurology
Currency : USD
2024 Revenue in Millions : 22
2023 Revenue in Millions : 32
Growth (%) : -30
Main Therapeutic Indication : Neurology
Currency : USD
2024 Revenue in Millions : 2,314
2023 Revenue in Millions : 1,836
Growth (%) : 26